Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964499 | 1.00 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL12526945 | 1.00 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL25942989 | 0.91 | CHRM2 (0.62) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL22054238 | 0.91 | CHRM2 (0.62) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL24716574 | 0.89 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL25892541 | 0.89 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL19583627 | 0.87 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL22077640 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL30576874 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3HSD11B1NR1H2 | |
| SCHEMBL27043844 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3HSD11B1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180117044-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8889854-B2 | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130296554-A1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117044-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | CHRM2 95/4885CHRM1 82/4885CHRM3 316/4885 |
| US-20130296554-A1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CDK17, UGT2B17 | CHRM2 3787/4885CHRM1 2696/4885CHRM3 2847/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | CHRM2 3258/4885CHRM1 2635/4885CHRM3 3326/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CHRM2 3258/4885CHRM1 2635/4885CHRM3 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.